Brown Advisory’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $6.89M | Buy |
53,920
+7,336
| +16% | +$916K | 0.01% | 474 |
|
|
2025
Q4 | $5.68M | Buy |
46,584
+4,673
| +11% | +$536K | 0.01% | 523 |
|
|
2025
Q3 | $4.2M | Sell |
41,911
-42,681
| -50% | -$3.84M | 0.01% | 555 |
|
|
2025
Q2 | $7.02M | Sell |
84,592
-207,209
| -71% | -$16.5M | 0.01% | 459 |
|
|
2025
Q1 | $23.7M | Sell |
291,801
-36,419
| -11% | -$3.26M | 0.03% | 295 |
|
|
2024
Q4 | $29.6M | Sell |
328,220
-687,813
| -68% | -$66.6M | 0.04% | 285 |
|
|
2024
Q3 | $100M | Sell |
1,016,033
-74,328
| -7% | -$7.3M | 0.13% | 131 |
|
|
2024
Q2 | $101M | Sell |
1,090,361
-578,741
| -35% | -$51.9M | 0.13% | 124 |
|
|
2024
Q1 | $158M | Buy |
1,669,102
+107,922
| +7% | +$10M | 0.21% | 88 |
|
|
2023
Q4 | $139M | Sell |
1,561,180
-51,664
| -3% | -$3.84M | 0.2% | 93 |
|
|
2023
Q3 | $118M | Sell |
1,612,844
-136,602
| -8% | -$10.9M | 0.19% | 99 |
|
|
2023
Q2 | $146M | Sell |
1,749,446
-166,191
| -9% | -$13.9M | 0.23% | 94 |
|
|
2023
Q1 | $146M | Buy |
1,915,637
+34,532
| +2% | +$2.87M | 0.25% | 93 |
|
|
2022
Q4 | $156M | Buy |
1,881,105
+910,850
| +94% | +$73.7M | 0.29% | 85 |
|
|
2022
Q3 | $77M | Buy |
970,255
+889,912
| +1,108% | +$75M | 0.15% | 125 |
|
|
2022
Q2 | $5.97M | Buy |
80,343
+1,511
| +2% | +$113K | 0.01% | 434 |
|
|
2022
Q1 | $7.08M | Buy |
78,832
+24,487
| +45% | +$2.26M | 0.01% | 433 |
|
|
2021
Q4 | $6.08M | Sell |
54,345
-13,265
| -20% | -$1.6M | 0.01% | 455 |
|
|
2021
Q3 | $8.5M | Sell |
67,610
-5,235
| -7% | -$674K | 0.01% | 386 |
|
|
2021
Q2 | $9.86M | Buy |
72,845
+2,095
| +3% | +$275K | 0.01% | 380 |
|
|
2021
Q1 | $9.6M | Buy |
70,750
+15,429
| +28% | +$2.31M | 0.02% | 357 |
|
|
2020
Q4 | $7.79M | Buy |
55,321
+45,810
| +482% | +$5.87M | 0.01% | 374 |
|
|
2020
Q3 | $1.06M | Buy |
9,511
+100
| +1% | +$11.2K | ﹤0.01% | 602 |
|
|
2020
Q2 | $1.05M | Buy |
9,411
+1,055
| +13% | +$104K | ﹤0.01% | 585 |
|
|
2020
Q1 | $647K | Buy |
8,356
+600
| +8% | +$53.1K | ﹤0.01% | 636 |
|
|
2019
Q4 | $738K | Sell |
7,756
-37
| -0.5% | -$3.2K | ﹤0.01% | 694 |
|
|
2019
Q3 | $594K | Sell |
7,793
-630
| -7% | -$52.4K | ﹤0.01% | 713 |
|
|
2019
Q2 | $739K | Buy |
8,423
+167
| +2% | +$14.2K | ﹤0.01% | 690 |
|
|
2019
Q1 | $747K | Hold |
8,256
| – | – | ﹤0.01% | 877 |
|
|
2018
Q4 | $592K | Buy |
8,256
+5,349
| +184% | +$431K | ﹤0.01% | 894 |
|
|
2018
Q3 | $279K | Hold |
2,907
| – | – | ﹤0.01% | 1175 |
|
|
2018
Q2 | $277K | Hold |
2,907
| – | – | ﹤0.01% | 1134 |
|
|
2018
Q1 | $255K | Sell |
2,907
-303
| -9% | -$27.7K | ﹤0.01% | 1032 |
|
|
2017
Q4 | $273K | Buy |
3,210
+303
| +10% | +$25.4K | ﹤0.01% | 1069 |
|
|
2017
Q3 | $252K | Buy |
+2,907
| New | +$233K | ﹤0.01% | 1052 |
|
|
2014
Q2 | – | Sell |
-2,550
| Closed | -$121K | – | 1009 |
|
|
2014
Q1 | $121K | Hold |
2,550
| – | – | ﹤0.01% | 907 |
|
|
2013
Q4 | $111K | Buy |
+2,550
| New | +$106K | ﹤0.01% | 868 |
|
Other funds holding XBI
Brown Advisory's XBI Position: Q1 2026 in Review
Brown Advisory increased its State Street SPDR S&P Biotech ETF (XBI) stake by 16% in Q1 2026, buying an estimated $916K and bringing the position to 53,920 shares worth $6.89M. The position accounts for 0.01% of the portfolio, ranked #474.
Brown Advisory first reported a position in XBI in Q4 2013 and has held it in 37 quarters since. The position peaked at $158M in Q1 2024. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- Brown Advisory held 53,920 shares of State Street SPDR S&P Biotech ETF worth $6.89M as of Q1 2026.
- Brown Advisory bought 7,336 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $916K.
- State Street SPDR S&P Biotech ETF made up 0.01% of Brown Advisory's portfolio in Q1 2026, its #474 holding.
- Brown Advisory first reported a position in State Street SPDR S&P Biotech ETF in Q4 2013 and has held it in 37 quarters since.
- Brown Advisory's State Street SPDR S&P Biotech ETF position peaked at $158M in Q1 2024.
- 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on Brown Advisory's 13F filing for Q1 2026, filed 15 May 2026.